Fig. 5.

CINMs-based PTT/PDT combination therapy. A Synthetic procedures and therapeutic mechanisms of Ni₃S₂/Cu_1.8S@HA. B Intracellular ROS and hypoxia levels in Mda-Mb-231 cells under normal and hypoxic conditions. NC10@HA represents Ni₃S₂ NPs doped with 10% Cu²⁺. Reproduced with permission [146]. Copyright 2021, American Chemical Society. C Schematic illustration of the in vivo experiment of CuO/Cu₂O TNCs against drug-resistant lung cancer. D Viabilities of H69AR cells treated with anti-EGFR-CuO/Cu₂O TNCs under dark and NIR light conditions at 37 and 4 °C, respectively (**p < 0.01 and ***p < 0.001). Reproduced with permission [26]. Copyright 2021, American Chemical Society. E Synthetic procedures and therapeutic mechanisms of HCuS-TH302@PDA-Ce6/TPP NPs. F Cellular uptake and mitochondrial co-localization of HCuS@PDA-Ce6 NPs and HCuS@PDA-Ce6/TPP NPs in B6F6 cells. MTG represents Mito-Tracker Green, a mitochondrial staining dye. Reproduced with permission [142]. Copyright 2022, Springer Nature. G Synthetic procedures and therapeutic mechanisms of NP-Cu as an endogenous H₂S-responsive intelligent nanoplatform. Reproduced with permission [147]. Copyright 2022, American Chemical Society